NAVAMEDIC (NAVA.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:NAVA - NO0010205966 - Common Stock
23.1 NOK
-1.5 (-6.1%)
We assign a fundamental rating of 3 out of 10 to NAVA. NAVA was compared to 54 industry peers in the Pharmaceuticals industry. While NAVA seems to be doing ok healthwise, there are quite some concerns on its profitability. NAVA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NAVA had negative earnings in the past year.
In the past year NAVA had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: NAVA reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: NAVA reported negative operating cash flow in multiple years.
1.2 Ratios
NAVA has a Return On Assets of -6.84%. This is in the lower half of the industry: NAVA underperforms 68.52% of its industry peers.
NAVA's Return On Equity of -15.33% is on the low side compared to the rest of the industry. NAVA is outperformed by 70.37% of its industry peers.
NAVA's Return On Invested Capital of 5.11% is in line compared to the rest of the industry. NAVA outperforms 42.59% of its industry peers.
The Average Return On Invested Capital over the past 3 years for NAVA is below the industry average of 13.79%.
The 3 year average ROIC (10.14%) for NAVA is well above the current ROIC(5.11%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.84% | ||
| ROE | -15.33% | ||
| ROIC | 5.11% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
1.3 Margins
The Operating Margin of NAVA (4.03%) is worse than 66.67% of its industry peers.
In the last couple of years the Operating Margin of NAVA has grown nicely.
NAVA has a worse Gross Margin (37.23%) than 75.93% of its industry peers.
NAVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.03% | ||
| PM (TTM) | N/A | ||
| GM | 37.23% |
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), NAVA is creating some value.
NAVA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NAVA has more shares outstanding
NAVA has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.60 indicates that NAVA is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of NAVA (2.60) is comparable to the rest of the industry.
The Debt to FCF ratio of NAVA is 2.78, which is a good value as it means it would take NAVA, 2.78 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 2.78, NAVA is doing good in the industry, outperforming 66.67% of the companies in the same industry.
A Debt/Equity ratio of 0.33 indicates that NAVA is not too dependend on debt financing.
NAVA has a Debt to Equity ratio of 0.33. This is in the better half of the industry: NAVA outperforms 62.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 2.6 |
ROIC/WACC0.61
WACC8.34%
2.3 Liquidity
A Current Ratio of 1.30 indicates that NAVA should not have too much problems paying its short term obligations.
NAVA has a Current ratio of 1.30. This is comparable to the rest of the industry: NAVA outperforms 51.85% of its industry peers.
NAVA has a Quick Ratio of 1.30. This is a bad value and indicates that NAVA is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.71, NAVA is doing worse than 72.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.71 |
3. Growth
3.1 Past
The earnings per share for NAVA have decreased strongly by -236.79% in the last year.
Looking at the last year, NAVA shows a decrease in Revenue. The Revenue has decreased by -3.67% in the last year.
Measured over the past years, NAVA shows a very strong growth in Revenue. The Revenue has been growing by 23.00% on average per year.
EPS 1Y (TTM)-236.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.47%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%-12.17%
3.2 Future
The Earnings Per Share is expected to grow by 31.39% on average over the next years. This is a very strong growth
NAVA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.79% yearly.
EPS Next Y-144.15%
EPS Next 2Y-24.66%
EPS Next 3Y10.9%
EPS Next 5Y31.39%
Revenue Next Year10.54%
Revenue Next 2Y18.87%
Revenue Next 3Y17.55%
Revenue Next 5Y12.79%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
NAVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
NAVA is valuated quite expensively with a Price/Forward Earnings ratio of 31.45.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NAVA indicates a slightly more expensive valuation: NAVA is more expensive than 64.81% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.03. NAVA is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 31.45 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NAVA is valued a bit cheaper than the industry average as 75.93% of the companies are valued more expensively.
79.63% of the companies in the same industry are more expensive than NAVA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.85 | ||
| EV/EBITDA | 9.92 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.66%
EPS Next 3Y10.9%
5. Dividend
5.1 Amount
NAVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
OSL:NAVA (12/23/2025, 7:00:00 PM)
23.1
-1.5 (-6.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners23.77%
Inst Owner ChangeN/A
Ins Owners12.68%
Ins Owner ChangeN/A
Market Cap553.94M
Revenue(TTM)523.56M
Net Income(TTM)-33.20M
Analysts82.86
Price Target36.72 (58.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.23%
Min Revenue beat(2)-7.18%
Max Revenue beat(2)-5.28%
Revenue beat(4)0
Avg Revenue beat(4)-8.08%
Min Revenue beat(4)-17.93%
Max Revenue beat(4)-1.92%
Revenue beat(8)2
Avg Revenue beat(8)-3.62%
Revenue beat(12)4
Avg Revenue beat(12)-1.68%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10%
PT rev (3m)-10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-118.33%
EPS NY rev (1m)-36.59%
EPS NY rev (3m)-343.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.14%
Revenue NY rev (1m)-0.52%
Revenue NY rev (3m)-1.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 31.45 | ||
| P/S | 1.06 | ||
| P/FCF | 13.85 | ||
| P/OCF | 12.77 | ||
| P/B | 2.56 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.92 |
EPS(TTM)-1.91
EYN/A
EPS(NY)0.73
Fwd EY3.18%
FCF(TTM)1.67
FCFY7.22%
OCF(TTM)1.81
OCFY7.83%
SpS21.83
BVpS9.03
TBVpS-1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.84% | ||
| ROE | -15.33% | ||
| ROCE | 6.63% | ||
| ROIC | 5.11% | ||
| ROICexc | 5.98% | ||
| ROICexgc | 90.24% | ||
| OM | 4.03% | ||
| PM (TTM) | N/A | ||
| GM | 37.23% | ||
| FCFM | 7.64% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
ROICexc(3y)12.6%
ROICexc(5y)N/A
ROICexgc(3y)98.8%
ROICexgc(5y)N/A
ROCE(3y)13.17%
ROCE(5y)N/A
ROICexgc growth 3Y90.11%
ROICexgc growth 5YN/A
ROICexc growth 3Y12.82%
ROICexc growth 5YN/A
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
F-Score4
Asset Turnover1.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.15 | ||
| Cap/Depr | 8.34% | ||
| Cap/Sales | 0.65% | ||
| Interest Coverage | 2.91 | ||
| Cash Conversion | 69.98% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.71 | ||
| Altman-Z | 2.6 |
F-Score4
WACC8.34%
ROIC/WACC0.61
Cap/Depr(3y)19.25%
Cap/Depr(5y)40.99%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-236.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.47%
EPS Next Y-144.15%
EPS Next 2Y-24.66%
EPS Next 3Y10.9%
EPS Next 5Y31.39%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%-12.17%
Revenue Next Year10.54%
Revenue Next 2Y18.87%
Revenue Next 3Y17.55%
Revenue Next 5Y12.79%
EBIT growth 1Y-55.6%
EBIT growth 3Y40.35%
EBIT growth 5YN/A
EBIT Next Year15.84%
EBIT Next 3Y37.82%
EBIT Next 5Y26.96%
FCF growth 1Y29.54%
FCF growth 3YN/A
FCF growth 5Y24.61%
OCF growth 1Y30.76%
OCF growth 3YN/A
OCF growth 5Y25.36%
NAVAMEDIC / NAVA.OL FAQ
Can you provide the ChartMill fundamental rating for NAVAMEDIC?
ChartMill assigns a fundamental rating of 3 / 10 to NAVA.OL.
What is the valuation status for NAVA stock?
ChartMill assigns a valuation rating of 2 / 10 to NAVAMEDIC (NAVA.OL). This can be considered as Overvalued.
What is the profitability of NAVA stock?
NAVAMEDIC (NAVA.OL) has a profitability rating of 3 / 10.